Kuang-Chi Technologies (002625) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
19 Dec, 2025Executive summary
Revenue for H1 2024 reached ¥852 million, up 1.07% year-over-year; net profit attributable to shareholders was ¥361 million, up 20.33% year-over-year; adjusted net profit (excluding non-recurring items) grew 30.53% year-over-year.
The company remains a leading supplier in the advanced metamaterials equipment sector, with stable production and delivery, and continued innovation in R&D and manufacturing.
Major contracts signed during the period totaled over ¥720 million, and a new automotive testing system was launched in partnership with a key industry player.
Financial highlights
Operating income: ¥852 million, up 1.07% year-over-year.
Net profit attributable to shareholders: ¥361 million, up 20.33% year-over-year.
Adjusted net profit: ¥356 million, up 30.53% year-over-year.
Operating cash flow: ¥320 million, a significant improvement from a negative ¥66 million in the prior year.
Basic and diluted EPS: ¥0.17, up 21.43% year-over-year.
Gross margin for main business: 53.39%, up 8.45 percentage points year-over-year.
Outlook and guidance
The company expects continued strong demand for advanced metamaterials equipment, driven by national policy and industry upgrades.
Ongoing expansion of production capacity (709 Base Phase II) is expected to further enhance delivery and efficiency.
Latest events from Kuang-Chi Technologies
- Strong revenue and profit growth supported by major new contracts and robust demand.002625
Q3 202519 Dec 2025 - Net profit rose 11.77% to ¥652 million on 4.25% revenue growth, with strong R&D gains.002625
Q4 202419 Dec 2025 - Revenue and net profit rose, with strong margins and major new contracts signed.002625
Q2 202520 Aug 2025 - Net profit rose 19.48% year-over-year in Q3 2024, driven by robust metamaterials growth.002625
Q3 202413 Jun 2025 - Revenue and profit grew solidly in Q1 2025, driven by new metamaterial contracts.002625
Q1 20256 Jun 2025